

**Remarks**

Claims 1-20 are pending.

The Office action required restriction to one of 3 inventions defined by claim groups. Applicants elect the invention of Group I, allegedly drawn to methods "of administering an agent to a mammal with an allergic or inflammatory disease and the agent." Group I was identified in the Office action as including present claims 1-14 and 20.

The Office action further required three species elections. The first, referred to as "Species A," required election of one type of component in claims 5-7 and 14. The second, referred to as "Species B," required election of agents capable of inhibiting ARG1 or agents capable of inhibiting CAT2. The third, referred to as "Species C," required election of  $\alpha$ -difluoromethylornithine, lysine or a cationic polypeptide.


Applicants elect, for Species A, a cationic amino acid transporter, as recited in claim 6. Applicants submit that at least claims 1-4, 6, 8, 10, 12-14 and 20 are readable on the elected species.

Applicants elect, for Species B, agents capable of inhibiting CAT2, as recited in claim 10. Applicants submit that at least 1-4, 6, 8, 10, 13-14 and 20 are readable on the elected species.

Applicants elect, for Species C, lysine, as recited in claim 12. Applicants submit that at least claims 1-4, 6, 12-14 and 20 are readable on the elected species.

Examiner Lin is invited to telephone the undersigned attorney to discuss any remaining issues.

Respectfully submitted,



Brian Fairchild, Ph.D.  
Attorney for Applicants  
Kirkpatrick & Lockhart Nicholson  
Graham LLP  
State Street Financial Center  
One Lincoln Street  
Boston, Massachusetts 02111-2950

Date: July 27, 2006  
Reg. No. 48,645

Tel. No.: (617) 261-3169  
Fax No.: (617) 261-3175